Kluger, H. M., Algazi, A. P., Balaraman, R., Buchbinder, E. I., Chai-Ho, W., Chen, M. F., Daniels, G. A., Hadid, T., Hernandez-Aya, L. F., Djuretic, I., Mehnert, J. M., Morgensztern, D., Olson, D., Poklepovic, A. S., Rock, A., Spigel, D. R., Sznol, M., Weiss, S. A., Liu, E., Ward, J. (2026). Phase 1A/B study of AB248, a CD8+ selective IL-2 mutein fusion protein, alone or in combination with pembrolizumab, in patients with advanced solid tumor malignancies.. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2026.44.16_suppl.2616